StoP-AD Team

Stop AD team

John Breitner was recruited to the Douglas to lead a new Centre for Studies on Prevention of Alzheimer’s Disease (StoP-AD). The Centre seeks measurement and detection of change in biomarkers thought to reveal the progress of presymptomatic Alzheimer’s disease. With such ability to measure change, the Centre undertakes clinical trials for Pre-symptomatic Evaluation of Novel or Experimental Treatments for AD (PREVENT-AD).

John Breitner has authored over 200 publications and has mentored more than 15 doctoral and post-doctoral students, almost all of whom have gone on to hold full-time academic appointments.

Research Team

John Breitner, MD

Associate Directors
Pierre Étienne, MD
Judes Poirier, PhD


Dr. Sylvia Villeneuve, Collaborating Investigator
Prof. Alan Evans, Collaborating Investigator
Dr. Rick Hoge, Collaborating Investigator
Prof. Gerhard Multhaup, Collaborating Investigator
Dr. Mallar Chakravarty, Collaborating Investigator
Dr. M. Natasha Rajah, Collaborating Investigator
Dr. Pedro Rosa-Neto, Collaborating Investigator
Dr. Pierre Bellec, Collaborating Investigator (Université de Montréal)
Dr. Pierre Orban, Collaborating Investigator (Université de Montréal)
Dr Christine Lucas-Tardif, Collaborating Investigator (McGill University)
Dr Nathan Spreng, Collaborating Investigator (McGill University)
Dr. Jeannie-Marie Leoutsakos, Collaborating Investigator (Johns Hopkins)
Dr. Jason Brandt, Collaborating Investigator (Johns Hopkins)

Research Coordinator

Jennifer Tremblay-Mercier


Cécile Madjar, Associate Programmer
Justin Kat, Associate Programmer


Marie-Elyse Lafaille-Magnan, Neurology and Neurosurgery PhD Candidate
Angela Tam, PhD student in the Integrated Program in Neuroscience (co-supervised by Dr. Bellec)
Pierre-François Meyer, PhD student in the Integrated Program in Neuroscience (co-supervised by Dr. Villeneuve)

Alzheimer's disease research links

McGill Logo

CIUSSS ouest montreal logo


  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre